{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:24:37Z","timestamp":1789575877466,"version":"build-2803163510"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the efficacy and safety of venetoclax (Ven) in combination with hypomethylating agents (HMAs) for the treatment of mixed-phenotype acute leukemia (MPAL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From July 2023 to April 2025, 4 newly diagnosed MPAL patients treated with Ven combined with HMAs at the Affiliated Cancer Hospital of Zhengzhou University, Luoyang Central Hospital and Anyang Regional Hospital were retrospectively analyzed to determine the efficacy and safety of this treatment. The relevant published studies were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study included four patients (2 males, 2 females) with a median age of 47 years (range: 40\u201380 years). Three patients were classified as having B\/myeloid MPAL, and one was classified as having T\/myeloid MPAL. All patients achieved complete remission (CR) after one cycle of venetoclax combined with HMAs. Notably, Patient 3, who tested positive for the BCR::ABL1 fusion gene, received additional tyrosine kinase inhibitor (TKI) therapy. The median duration of myelosuppression during induction therapy was 26 days (range: 7\u201336). Patients 1 and 4 developed infections during induction, which were controlled with aggressive antimicrobial treatment and supportive care. In contrast, Patients 2 and 3 tolerated the regimen well without significant adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The treatment of MPAL with Ven combined with HMAs achieved a high remission rate and can be used as an alternative treatment for MPAL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1693061","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:19:01Z","timestamp":1761542341000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Venetoclax combined with hypomethylating agents for the treatment of newly diagnosed with mixed-phenotype acute leukemia and a literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Ruihua","family":"Mi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuli","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongbei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-551465","article-title":"How I treat mixed-phenotype acute leukemia","volume":"125","author":"Wolach","year":"2015","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2015.03.012","article-title":"Survival of patients with mixed phenotype acute leukemias: A large population-based study","volume":"39","author":"Shi","year":"2015","journal-title":"Leuk Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v11.i26.6200","article-title":"T\/myeloid mixed-phenotype acute leukemia treated with venetoclax and decitabine: A case report","volume":"11","author":"Park","year":"2023","journal-title":"World J Clin cases"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03637.x","article-title":"The anti-apoptotic genes Bcl-X(L) and Bcl-2 are overexpressed and contribute to chemoresistance of nonproliferating leukemic CD34+ cells","volume":"118","author":"Konopleva","year":"2002","journal-title":"Br J Hematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15802","article-title":"Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukemia in the post-BCR inhibitor setting: a UK wide analysis","volume":"185","author":"Eyre","year":"2019","journal-title":"Br J Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-475855","article-title":"ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia","volume":"121","author":"Vandenberg","year":"2013","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukemia: a nonrandomized, open-label, phase 1b study","volume":"19","author":"Dinardo","year":"2018","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-574566","article-title":"ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia","volume":"124","author":"Peirs","year":"2014","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.608","article-title":"Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-cell acute lymphoblastic leukemia","volume":"20","author":"Richard-Carpentier","year":"2020","journal-title":"CL LYMPH MYELOM LEUK"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-0236","article-title":"Bcl-2 is a therapeutic target for hypodiploid B-lineage acute lymphoblastic leukemia","volume":"79","author":"Diaz-Flores","year":"2019","journal-title":"Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16622","article-title":"Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukemia and mixed phenotype acute leukemia","volume":"189","author":"Wu","year":"2020","journal-title":"BRIT J Haematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1159\/000519882","article-title":"Venetoclax in combination with hypomethylating agents for the treatment of treatment-naive B\/myeloid mixed-phenotype acute leukemia and relapsed\/refractory acute myeloid leukemia: A report of 3 cases","volume":"67","author":"Wang","year":"2022","journal-title":"CHEMOTHERAPY"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020102","article-title":"Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML","volume":"142","author":"Xie","year":"2023","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2964","article-title":"Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-na\u00efve acute myeloid leukemia who are ineligible for intensive chemotherapy","volume":"40","author":"Brackman","year":"2022","journal-title":"Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0058-4","article-title":"Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis","volume":"32","author":"Maruffi","year":"2018","journal-title":"Leukemia"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1693061\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:19:02Z","timestamp":1761542342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1693061\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":16,"alternative-id":["10.3389\/fonc.2025.1693061"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1693061","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"article-number":"1693061"}}